Use of #Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children
#RSV

📌 On August 3, 2023, the ACIP recommended nirsevimab for infants aged <8 months born during or entering their first RSV season and for infants and children aged 8–19 months who are at increased risk of severe RSV disease entering their second RSV season.

https://www.cdc.gov/mmwr/volumes/72/wr/mm7234a4.htm

AAP publishes guidance on #nirsevimab for #children

📌 The AAP recommended that all infants receive nirsevimab to protect against severe RSV.
📌 The monoclonal antibody was recently approved by the FDA and recommended by the CDC.
📌 The AAP recommends a single dose for infants younger than 8mo born during or entering their first RSV season, and for infants and children aged 8-19mo who are at an increased risk for severe RSV disease

https://www.healio.com/news/pediatrics/20230816/aap-publishes-guidance-on-nirsevimab-for-children?utm_source=selligent

#FDA advisory panel approves #nirsevimab for use in infantile #RSV #infections

https://www.naturalnews.com/2023-06-14-fda-panel-supports-rsv-antibody-drug-infants.html

#Beyfortus riduce dell’83% i ricoveri dei #neonati per #RSV

📌 Dal nuovo studio dai quali emerge come Beyfortus (#nirsevimab) abbia ridotto dell’83% i ricoveri di neonati colpiti da malattie respiratorie legate al virus respiratorio sinciziale (RSV).

📌 Beyfortus è un anticorpo monoclonale che in Europa ha già ottenuto l’approvazione per la prevenzione della bronchiolite e polmonite, causate dal virus respiratorio sinciziale nei neonati e nei bambini.

https://www.dailyhealthindustry.it/sanofi-e-astrazeneca-beyfortus-riduce-dell83-i-ricoveri-dei-neonati-per-rsv-ID28110.html

New research article in The Lancet Infectious Diseases>

#Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2823%2900062-2/fulltext

#RSV